Amneal Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

5/8/25 4:21:09 PM ET

$AMRX

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $AMRX alert in real time by email

amrx-20250508

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 8, 2025

AMNEAL PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-38485

93-4225266

(State or other jurisdiction
of incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

400 Crossing Blvd

Bridgewater, NJ 08807

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (908) 947-3120

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Class A Common Stock, par value $0.01 per share

AMRX

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07

Submission of Matters to a Vote of Security Holders.

Amneal Pharmaceuticals, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) on May 6, 2025. Each of the proposals was approved, and each of the director nominees was elected, by the vote of the stockholders at the Annual Meeting as follows:

Proposal 1: To elect the following director nominees to hold office until the 2025 Annual Meeting of Stockholders and until their respective successors are elected and qualified:




	For		Against		Abstain	Broker Non-Votes
Emily Peterson Alva		258,746,677		1,549,356	25,468		29,134,445
Deb Autor		258,775,698		1,519,874	25,929		29,134,445
J. Kevin Buchi		257,353,899		2,740,560	227,042		29,134,445
Jeff George		258,597,328		1,697,135	27,038		29,134,445
John Kiely		257,525,966		2,568,488	227,047		29,134,445
Paul Meister		239,786,615		20,307,492	227,394		29,134,445
Ted Nark		257,861,624		2,225,579	234,298		29,134,445
Chintu Patel		259,451,886		840,909	28,706		29,134,445
Chirag Patel		259,263,024		1,029,755	28,722		29,134,445
Gautam Patel		256,035,302		4,257,416	28,783		29,134,445
Shlomo Yanai		258,502,824		1,791,220	27,457		29,134,445

Proposal 2: To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers:




For	Against	Abstain	Broker Non-Votes
258,800,579	1,255,182	265,740	29,134,445

Proposal 3:Advisory vote to approve the Frequency of Future “Say on Pay” votes:




1 Year	2 Years	3 Years	Abstain	Broker Non-Votes
255,051,542	53,168	5,178,739	38,052	0

Proposal 4: To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025:




For	Against	Abstain	Broker Non-Votes
288,989,309	452,503	14,134	0

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: May 8, 2025	AMNEAL PHARMACEUTICALS, INC.

	By:	/s/ Jason B. Daly
	Name:	Jason B. Daly
	Title:	Executive Vice President, Chief Legal Officer and Corporate Secretary

Get the next $AMRX alert in real time by email

Date

Price Target

Rating

Analyst

6/6/2025

$12.00

Buy

Goldman

2/24/2025

$9.00 → $12.00

Neutral → Overweight

Analyst

9/6/2024

$9.00

Underweight → Neutral

JP Morgan

Amneal Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

Chat with this insight

Recent Analyst Ratings for
$AMRX

$AMRX
Press Releases

Fastest customizable press release news feed in the world

Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences

Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension

Amneal to Participate at Upcoming Investor Conferences in June

$AMRX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Patel Gautam sold $761,146 worth of shares (94,906 units at $8.02), decreasing direct ownership by 6% to 1,609,144 units (SEC Form 4)

Director Patel Gautam sold $452,537 worth of shares (56,426 units at $8.02), decreasing direct ownership by 3% to 1,704,050 units (SEC Form 4)

Executive Vice President Shah Nikita sold $372,481 worth of shares (49,140 units at $7.58), decreasing direct ownership by 11% to 388,929 units (SEC Form 4)

$AMRX
SEC Filings